Establishment of a novel tumor neoantigen prediction tool for personalized vaccine design

References

• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–10. doi:10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Kha QH, Le V-H, Hung TNK, Nguyen NTK, Le NQK. Development and validation of an explainable machine learning-based prediction model for drug–food interactions from chemical structures. Sensors (Basel). 2023;23(8):3962. doi:10.3390/s23083962.
   PubMed Web of Science ®Google Scholar
• Le NQ, Nguyen TT, Ou YY. Identifying the molecular functions of electron transport proteins using radial basis function networks and biochemical properties. J Mol Graph Model. 2017;73:166–178. doi:10.1016/j.jmgm.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51–88. doi:10.1146/annurev.immunol.17.1.51.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber W-J, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–581. doi:10.1038/nature13988.
   PubMed Web of Science ®Google Scholar
• Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL, Griffith M. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 2019;11(1):56. doi:10.1186/s13073-019-0666-2.
   PubMed Web of Science ®Google Scholar
• Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11. doi:10.1186/s13073-016-0264-5.
   PubMed Web of Science ®Google Scholar
• Bais P, Namburi S, Gatti DM, Zhang X, Chuang JH. CloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics. 2017;33(19):3110–3112. doi:10.1093/bioinformatics/btx375.
   PubMed Web of Science ®Google Scholar
• Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS data mining pipeline for cancer immunology and immunotherapy. Bioinformatics. 2017;33(19):3140–3141. doi:10.1093/bioinformatics/btx377.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lyu X, Wu J, Yang X, Wu S, Zhou J, Gu X, Su Z, Chen S. TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection. R Soc Open Sci. 2017;4(4):170050. doi:10.1098/rsos.170050.
   PubMed Web of Science ®Google Scholar
• Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–3368. doi:10.4049/jimmunol.1700893.
   PubMed Web of Science ®Google Scholar
• Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol. 2018;37:55–63. doi:10.1038/nbt.4313.
   Web of Science ®Google Scholar
• O’Donnell TJ, Rubinsteyn A, Laserson U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 2020;11(4):418–419. doi:10.1016/j.cels.2020.09.001.
   PubMed Web of Science ®Google Scholar
• Zhao W, Sher X, Peters B. Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes. PLoS Comput Biol. 2018;14(11):e1006457. doi:10.1371/journal.pcbi.1006457.
   PubMed Web of Science ®Google Scholar
• Vitiello A, Zanetti M. Neoantigen prediction and the need for validation. Nat Biotechnol. 2017;35(9):815–817. doi:10.1038/nbt.3932.
   PubMed Web of Science ®Google Scholar
• Diao K, Chen J, Wu T, Wang X, Wang G, Sun X, Zhao X, Wu C, Wang J, Yao H, et al. Seq2Neo: a comprehensive pipeline for cancer neoantigen immunogenicity prediction. IJMS. 2022;23(19):11624. doi:10.3390/ijms231911624.
   Google Scholar
• Wu J, Wang W, Zhang J, Zhou B, Zhao W, Su Z, Gu X, Wu J, Zhou Z, Chen S, et al. DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA-Peptide binding and immunogenicity. Front Immunol. 2019;10:2559. doi:10.3389/fimmu.2019.02559.
   PubMed Web of Science ®Google Scholar
• Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Keşmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013;9(10):e1003266. doi:10.1371/journal.pcbi.1003266.
   PubMed Web of Science ®Google Scholar
• Li G, Iyer B, Prasath VBS, Ni Y, Salomonis N. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity. Brief Bioinform. 2021;22(6):bbab160. doi:10.1093/bib/bbab160.
   Web of Science ®Google Scholar
• Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, Kim H-H, Choi J-H, Kim H-K, Yu W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–1396. doi:10.1016/S1470-2045(14)70473-5.
   PubMed Web of Science ®Google Scholar
• Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, Cen L, Tian M, Xu Q, Chen F, et al. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk Gastric/gastroesophageal junction cancer. Adv Sci (Weinh). 2022;10(1):e2203298. doi:10.1002/advs.202203298.
   PubMedGoogle Scholar
• Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818–34.e13. doi:10.1016/j.cell.2020.09.015.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–752. doi:10.1038/nm.3161.
   PubMed Web of Science ®Google Scholar
• Supabphol S, Li L, Goedegebuure SP, Gillanders WE. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert Opin Investig Drugs. 2021;30(5):529–41. doi:10.1080/13543784.2021.1896702.
   PubMed Web of Science ®Google Scholar
• Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–229. doi:10.1038/s41571-020-00460-2.
   PubMed Web of Science ®Google Scholar
• Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria J-C, Postel-Vinay S. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22(17):4309–4321. doi:10.1158/1078-0432.CCR-16-0903.
   PubMed Web of Science ®Google Scholar
• Gfeller D, Guillaume P, Michaux J, Pak H-S, Daniel RT, Racle J, Coukos G, Bassani-Sternberg M. The length distribution and multiple specificity of naturally presented HLA-I ligands. J Immunol. 2018;201(12):3705–3716. doi:10.4049/jimmunol.1800914.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D. Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol. 2017;13(8):e1005725. doi:10.1371/journal.pcbi.1005725.
   PubMed Web of Science ®Google Scholar
• Rasmussen M, Fenoy E, Harndahl M, Kristensen AB, Nielsen IK, Nielsen M, Buus S. Pan-specific prediction of peptide–MHC class I complex stability, a correlate of T cell immunogenicity. J Immunol. 2016;197(4):1517–1524. doi:10.4049/jimmunol.1600582.
   PubMed Web of Science ®Google Scholar
• Kriegeskorte N, Golan T. Neural network models and deep learning. Curr Biol. 2019;29(7):R231–R236. doi:10.1016/j.cub.2019.02.034.
   PubMed Web of Science ®Google Scholar
• Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future. Mol Cell Proteom. 2021;20:100022. doi:10.1074/mcp.R120.002309.
   PubMed Web of Science ®Google Scholar
• Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120(6):3210–3229. doi:10.1021/acs.chemrev.9b00472.
   PubMed Web of Science ®Google Scholar